Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Davies F, et al. Among authors: farrelly e. Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10. Ann Hematol. 2021. PMID: 33970288 Free PMC article.
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. Hari P, et al. Among authors: farrelly e. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29395837 Free article.
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK. Bell JA, et al. Among authors: farrelly e. Leuk Res. 2019 Mar;78:45-51. doi: 10.1016/j.leukres.2019.01.008. Epub 2019 Jan 24. Leuk Res. 2019. PMID: 30716655 Free article.
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. Chari A, et al. Among authors: farrelly e. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16. doi: 10.1016/j.clml.2019.09.625. Epub 2019 Oct 10. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31722839 Free article.
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.
Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Chari A, et al. Among authors: farrelly e. Expert Rev Hematol. 2020 Apr;13(4):421-433. doi: 10.1080/17474086.2020.1729734. Epub 2020 Mar 9. Expert Rev Hematol. 2020. PMID: 32148109
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
Raju A, Pimple P, Stafkey-Mailey D, Farrelly E, Shetty S. Raju A, et al. Among authors: farrelly e. Diabetes Ther. 2022 Jan;13(1):25-42. doi: 10.1007/s13300-021-01173-0. Epub 2021 Nov 2. Diabetes Ther. 2022. PMID: 34727356 Free PMC article.
85 results